Lantheus nabs $300K to develop capsule for colon cancer screening

Lisa Fratt | | Health Imaging | Molecular Imaging
Lantheus Medical Imaging has been selected to receive a $300,000 Massachusetts-Israel Innovation Partnership (MIIP) grant to develop a 3D capsule for colorectal cancer screening.

Lantheus will receive the grant upon signing a collaboration agreement with Check-Cap to develop and manufacture a 3D imaging capsule to screen for polyps and lesions associated with colorectal cancer. Check-Cap, which is based in Mount Carmel, Israel, is being awarded a grant from the Office of the Chief Scientist in Israel.

MIIP is a formal collaboration between the State of Israel and Commonwealth of Massachusetts focused on supporting innovation and entrepreneurship between Massachusetts’ and Israel’s life sciences, clean energy and technology sectors. The grant is made possible by Massachusetts Gov. Deval Patrick, Israel’s Chief Scientist Avi Hasson, the U.S.-Israel Science and Technology Foundation and the Massachusetts Technology Collaborative.

Lisa Fratt

Related Content

New radiopharmaceutical targeted at gastrointenstinal cancers yields impressive results
New PET method combines antibody with radioactive isotope to improve lung cancer detection
ALS drug repurposed for PET imaging
New radiotracer has 'incredible potential' to improve management of spinal cord injuries
Frontotemporal dementia often misdiagnosed due to misinterpretations of imaging
Endometriosis imaging agent impresses at clinical trials

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.